![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, October 19, 2006 11:35:07 PM
This misses the point. If ampa-upmodulation proves safe and effective, the pie is limitless with markets of many tens of billions of dollars in a rapidly growing aging population. Cognitive improvements in the elderly with and without Alzheimers alone is a ten billion dollar indication in the US alone--maybe bigger and growing. Schizophrenia, Depression, ADHD, sleep, autism, Fragile X, ALS, autism, Huntington's Disease, Parkinson's Disease all roll off the tongue as front line conditions with a hypo-glutamergic component. This is just scratching the surface.
Like SSRI's, a partial but not 'big enough' example, ampakines are an entirely new pharmacology. Assuming LLY wins a patent challenge in three or four years. So what? Did the overwhelming success of LLY's Prozac--first to market for an SSRI--doom the launches for Zoloft, Celexa, Lexapro or Paxil??? How about statins! Does the success of Lipitor(now generic) doom Zocor or Crestor???
For Cortex' structure(s) to capture even a small fraction of this huge market would turn us into a multi-billion dollar cap biotech stock--or more probable--simply bought out ala ICOS or IMNX. These are markets of staggering size. The least of Cortex' problems is what will happen to their use patents. Rest assured of another point as well . . . the more clinical success of LLY's or COR's program(s), the greater the number of companies challenging the use patents. Plus, Cortex just might hold on to their use patent estate.
Safe and effective are the two questions that will be answered in the next few years vis-a-vis ampa receptor upmoduulation. They will determine if we soar or sink . . . not what happens in the patent courts.
Recent RSPI News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 12:45:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 12:30:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:01:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 12:45:26 PM
FEATURED Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • Sep 10, 2024 11:00 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Nightfood Holdings Inc. Completes Major Step on Uplist Journey by Closing Strategic All-Stock Acquisition of CarryoutSupplies.com • NGTF • Sep 10, 2024 8:15 AM
Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • ELEM • Sep 9, 2024 9:34 AM
North Bay Resources Commences Gold Shipments, Fran Gold Project, British Columbia; Enters Taber Gold Mine JV, Sierra County, California • NBRI • Sep 9, 2024 9:15 AM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM